Blood and Lymphatic Cancer: Targets and Therapy
Blood and Lymphatic Cancer: Targets and Therapy 2018:8 11 On page 2, Table 1 was incorrectly presented. Table 1 should have been: 
Note: Over 50% inhibition is indicated by X. Abbreviations: aLL, acute lymphoblastic leukemia; CmL, chronic myeloid leukemia; TKIs, tyrosine kinase inhibitors; aBL1, abelson murine leukemia viral oncogene homolog 1; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFr, platelet-derived growth factor receptor; KIT, stem cell growth factor receptor; FLT3, fms-like tyrosine kinase 3; SrC, sarcoma kinase.
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